Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

DIASYS DIAGNOSTIC SYSTEMS

Develops, manufactures, and distributes diagnostic systems for clinical chemistry and immunoturbidimetry. Supplies hi... read more Featured Products: More products

Download Mobile App





DiaSys Showcases High Quality Diagnostic Reagents and System Solutions

By LabMedica International staff writers
Posted on 14 Nov 2023

DiaSys Diagnostic Systems GmbH (Holzheim, Germany) is presenting its comprehensive portfolio of clinical chemistry analyzers, reagents, calibrators and controls at MEDICA 2023.

DiaSys offers complete system solutions including analyzer, reagents, and software. At MEDICA 2023, DiaSys is highlighting the respons910 benchtop analyzer which has a throughput of 100 to 150 tests/hour and is ideal for laboratories with a test volume of up to 500 tests per shift. Its high onboard capacity of 30 different methods in mono- or twin-containers and 30 sample positions offers the necessary flexibility for everyday use. Alongside the respons910, DiaSys is showcasing the respons920 benchtop analyzer with higher speed and guaranteed throughput of 200 tests/h and 360 tests/hour with ISE. With an on-board capacity of 30 different methods in mono- or twin containers, 30 samples plus nine positions for calibrators, controls, or emergency samples, respons920 offers almost unlimited flexibility in organizing laboratory workflows.

DiaSys is also highlighting the respons940 automated random access clinical chemistry analyzer that offers a constant throughput of a minimum of 400 tests/h, independent of whether a mono- or two-component reagent is used. Together with modern software features, pre-programmed applications, and carry-over evasion lists, respons940 analyzer delivers high-quality results for a broad parameter portfolio. Among the company’s products being highlighted at the show is the DiaSys CRP FS liquid-stable immunoturbidimetric test with dedicated ready-to-use calibrators and controls that allow true differentiation of borderline cases. DiaSys has extended its cardiovascular risk assessment portfolio with two innovative new reagents, HDL-c direct FS and LDL-c direct FS. Both are homogenous assays for direct determination. DiaSys has also expanded the application range for its Total bile acids 21 FS reagent and now offers the assay for use in serum and stool samples.

Related Links:
DiaSys Diagnostic Systems

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.